Oric Pharmaceuticals, Inc. (ORIC): who owns it and who trades it
As of Nov 16, 2026, ORIC insiders reported 15 open-market sales worth $2.9M and no purchases in the last 12 months, with 86% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dominic Piscitelli (CFO), with $2.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Oric Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ORIC
181 funds and institutions reported ORIC shares worth $1.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Nextech Invest Ltd. with 6.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nextech Invest Ltd. | 7.16M | 6.92% | $77.6M | No change |
| BlackRock, Inc. | 6.82M | 6.59% | $73.9M | +14% |
| EcoR1 Capital, LLC | 6.73M | 6.50% | $72.9M | No change |
| T. Rowe Price Associates | 6.62M | 6.39% | $71.7M | +23% |
| Viking Global Investors LP | 5.13M | 4.95% | $55.5M | -12% |
| State Street Corp | 4.89M | 4.73% | $53M | +32% |
| SR One Capital Management, LP | 4.62M | 4.46% | $50M | +2% |
| Venrock Adviser, LLC | 4.32M | 4.17% | $46.8M | No change |
| NEA Management Company, LLC | 4.12M | 3.98% | $44.6M | No change |
| Vanguard Capital Management LLC | 3.95M | 3.82% | $42.8M | +7% |
| AIHC Capital Management Ltd | 3.83M | 3.70% | $41.5M | +56% |
| Alkeon Capital Management LLC | 3.74M | 3.61% | $40.5M | -17% |
| Column Group LLC | 3.54M | 3.42% | $38.3M | No change |
| Siren, L.L.C. | 3.00M | 2.90% | $32.5M | No change |
| FMR LLC (Fidelity) | 2.64M | 2.55% | $28.5M | +8% |
| Citadel Advisors LLC | 2.60M | 2.51% | $28.1M | +7% |
| Goldman Sachs Group Inc | 2.45M | 2.37% | $26.6M | +66% |
| Geode Capital Management, LLC | 2.09M | 2.02% | $22.6M | +14% |
| First Turn Management, LLC | 2.02M | 1.95% | $21.8M | No change |
| Orbimed Advisors LLC | 2.02M | 1.95% | $21.8M | -25% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ORIC insiders reported $0 of open-market purchases and $2.9M of sales. 86% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 20, 2026 | Dominic Piscitelli | CFO | Sale plan | 14,000 | $13.53 | $189K | Form 4 |
| Oct 1, 2026 | Richard A. Heyman | Director | Sale plan | 3,500 | $12.91 | $45.2K | Form 4 |
| Oct 1, 2026 | Richard A. Heyman | Director | Sale plan | 3,200 | $12.91 | $41.3K | Form 4 |
| Sep 28, 2026 | Dominic Piscitelli | CFO | Sale plan | 13,400 | $13.53 | $181K | Form 4 |
| Sep 24, 2026 | Dominic Piscitelli | CFO | Sale plan | 100 | $13.50 | $1.4K | Form 4 |
| Sep 24, 2026 | Dominic Piscitelli | CFO | Sale plan | 500 | $13.51 | $6.8K | Form 4 |
| Aug 26, 2026 | Dominic Piscitelli | CFO | Sale plan | 77,000 | $13.69 | $1.1M | Form 4 |
| Jul 24, 2026 | Richard A. Heyman | Director | Sale plan | 7,000 | $12.02 | $84.1K | Form 4 |
| Jul 24, 2026 | Richard A. Heyman | Director | Sale plan | 6,100 | $12.02 | $73.3K | Form 4 |
| Jul 6, 2026 | Richard A. Heyman | Director | Sale plan | 300 | $12.00 | $3.6K | Form 4 |
| Feb 24, 2026 | Dominic Piscitelli | CFO | Sale plan | 52,000 | $13.51 | $703K | Form 4 |
| Jan 16, 2026 | Richard A. Heyman | Director | Sale plan | 3,200 | $12.00 | $38.4K | Form 4 |
| Jan 16, 2026 | Richard A. Heyman | Director | Sale plan | 3,500 | $12.00 | $42K | Form 4 |
| Dec 16, 2025 | Pratik S Multani | Chief Medical Officer | Sale | 10,720 | $9.06 | $97.1K | Form 4 |
| Dec 16, 2025 | Jacob Chacko | CEO | Sale | 33,374 | $9.06 | $302K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Dominic Piscitelli | Chief Financial Officer | – | $2.1M | Oct 20, 2026 |
| Richard A. Heyman | Director | – | $328K | Oct 1, 2026 |
| Jacob Chacko | PRESIDENT AND CEO, Director | – | $302K | Dec 16, 2025 |
| Pratik S Multani | Chief Medical Officer | – | $97.1K | Dec 16, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ORIC short interest
High short interest. 10.4% of ORIC shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 51%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.73M ORIC shares were sold short, 10.4% of the shares outstanding, down 30.4% from the report before. At the average daily volume of 2.24M shares, buying them all back would take about 4.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.73M | 10.35% | -30% | 2.24M | 4.8 |
| Oct 15, 2026 | 15.42M | 14.88% | -5% | 1.47M | 10.5 |
| Sep 30, 2026 | 16.32M | 15.74% | -7% | 1.66M | 9.8 |
| Sep 15, 2026 | 17.53M | 16.91% | +2% | 1.23M | 14.2 |
| Aug 31, 2026 | 17.27M | 16.66% | -6% | 1.07M | 16.2 |
| Aug 14, 2026 | 18.39M | 17.74% | -16% | 1.68M | 11.0 |
| Jul 31, 2026 | 21.80M | 21.04% | -1% | 1.61M | 13.6 |
| Jul 15, 2026 | 22.05M | 21.30% | -0% | 1.63M | 13.5 |
| Jun 30, 2026 | 22.11M | 21.36% | +5% | 1.79M | 12.3 |
| Jun 15, 2026 | 21.06M | 20.34% | -4% | 2.04M | 10.3 |
| May 29, 2026 | 21.94M | 21.19% | No change | 1.27M | 17.2 |
| May 15, 2026 | 21.94M | 21.20% | -0% | 1.43M | 15.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Oric Pharmaceuticals company events
Oric Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 23, 2026.
- Oct 23, 2026AnnouncementThe Program Update covered updated data from the Company’s Phase 1b trial of enozertinib, as well as the Company’s plans to initiate a global Phase 3 registrational trial of enozertinib in the first half of 2027: Enozertinib Phase 1b Data in 1L EGFR Atypical NSCLC Enozertinib is being evaluated in… Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jul 30, 2026LeadershipThe Board of Directors of ORIC Pharmaceuticals, Inc. approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), in order to increase the number of shares reserved for issuance under the Inducement Plan. Filing
- Jun 22, 2026LeadershipORIC Pharmaceuticals, Inc. amended and restated its 2020 Equity Incentive Plan, effective as of June 18, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). Filing
- May 4, 2026ResultsReleased financial results. Filing
- Mar 31, 2026AnnouncementORIC Pharmaceuticals, Inc. presented a rinzimetostat (ORIC-944) program update on March 31, 2026. Filing
- Feb 23, 2026AnnouncementORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC to sell shares of the Company’s common stock, par value $0.0001 per share, from time to time, through an “at the market offering” program under which Jefferies acts as sales agent. Filing
- Feb 23, 2026ResultsReleased financial results. Filing
- Dec 8, 2025AnnouncementORIC Pharmaceuticals, Inc. presented an enozertinib (ORIC-114) program update on December 6, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Oric Pharmaceuticals financials
Famous investors that hold ORIC
4 of the 50 well-known investors we track reported holding ORIC in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $48M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 3.56M | $48M | 0.1% | -31% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.11M | $28.4M | 0.0% | -19% |
| Israel Englander · Millennium Management | Q3 2026 | 713,325 | $9.6M | 0.0% | +2% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 108,852 | $1.5M | 0.0% | +157% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ORIC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | EcoR1 Capital, LLC | 13G/A | 2.9% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.9% |
| Nov 16, 2026 | VIKING GLOBAL INVESTORS LP | 13G/A | 5.7% |
| Nov 16, 2026 | EcoR1 Capital, LLC | 13G/A | 2.9% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.9% |
| Nov 16, 2026 | VIKING GLOBAL INVESTORS LP | 13G/A | 5.7% |
Questions about Oric Pharmaceuticals, Inc. (ORIC) stock
Who owns the most ORIC stock?
The largest reported owner of Oric Pharmaceuticals, Inc. (ORIC) is Nextech Invest Ltd., with 6.9% of the company. In total, 181 funds and institutions reported holding ORIC at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ORIC insiders buying or selling?
In the last 12 months, ORIC insiders reported no open-market purchases and 15 sales worth $2.9M. The latest trade was on Oct 20, 2026. See every trade.
What is the short interest in ORIC?
As of Oct 30, 2026, 10.73M ORIC shares were sold short, 10.4% of the shares outstanding, down 30.4% from the report before. At the average daily volume of 2.24M shares, buying them all back would take about 4.8 trading days (days to cover). See the history.
Which famous investors hold ORIC?
4 of the 50 well-known investors we track reported ORIC in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Israel Englander. The largest position is worth $48M. See all holders.
Executive pay
Oric Pharmaceuticals's chief executive was paid a total of $5.6M for the year ended Dec 31, 2025, up 5% from $5.3M the year before. In the last 12 months, Oric Pharmaceuticals's executives and directors bought no stock on the open market and sold $2.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.